AXSM (Axsome Therapeutics) 3-1 Month Momentum %: 33.43% (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AXSM Axsome Therapeutics Inc AXSM
52 GF Score
Price $230.00
GF Value $225.51
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Axsome Therapeutics 3-1 Month Momentum %?

Axsome Therapeutics AXSM -2.97% 52 3-1 Month Momentum % is 33.43% as of Jul. 18, 2026. GuruFocus rates AXSM with a GF Score™ of 52/100 and a GF Value™ of $225.51 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,389 Biotechnology companies, Axsome Therapeutics ranks better than 93.81% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-18), Axsome Therapeutics's 3-1 Month Momentum % is 33.43%.

The industry rank for Axsome Therapeutics's 3-1 Month Momentum % or its related term are showing as below:

AXSM's 3-1 Month Momentum % is ranked better than
93.81% of 1389 companies
in the Biotechnology industry
Industry Median: -13.25 vs AXSM: 33.43

Axsome Therapeutics  (NAS:AXSM) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Axsome Therapeutics 3-1 Month Momentum % Related Terms

AXSM vs MDGL, IONS, BMRN: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Axsome Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Axsome Therapeutics 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's 3-1 Month Momentum % falls into.


AXSM
52GF Score
Axsome Therapeutics Inc AXSM
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Axsome Therapeutics  (NAS:AXSM) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of 33.43% mean?
Axsome Therapeutics (AXSM) has a 3-1 Month Momentum % of 33.43% as of Jul. 18, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Axsome Therapeutics and its competitors. According to the industry distribution chart, Axsome Therapeutics ranks #86 out of 1389 companies in the Biotechnology industry, placing it in the top 6.2%.
Is Axsome Therapeutics' 3-1 Month Momentum % too high?
Axsome Therapeutics' current 3-1 Month Momentum % is 33.43%. Based on the distribution chart, Axsome Therapeutics ranks #86 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' 3-1 Month Momentum % compare to MDGL and IONS?
According to the Biotechnology industry distribution chart, Axsome Therapeutics ranks #86 out of 1389 companies for 3-1 Month Momentum %. This places Axsome Therapeutics in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Axsome Therapeutics and its competitors. Axsome Therapeutics's current 3-1 Month Momentum % is 33.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Fairly Valued. The stock's GF Value™ is $225.51, compared to a current price of $230.00 — trading 2% above its estimated fair value. The current 3-1 Month Momentum % is 33.43%. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current 3-1 Month Momentum % is 33.43% as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Axsome Therapeutics (AXSM) Overvalued in 2026?

Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued. The current stock price of $230.00 is trading 2% above its estimated GF Value™ of $225.51. GuruFocus considers Axsome Therapeutics to be Fairly Valued.

Key valuation signals for AXSM:

  • 3-1 Month Momentum %: 33.43%
  • GF Value™: $225.51 vs. price of $230.00 (2% above fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Axsome Therapeutics Business Description

Address One World Trade Center, 29th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score

Get the complete analysis for AXSM

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$230.00
Price
$225.51
GF Value